ICUI ICU MEDICAL INC/DE
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883984 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-5.9%
TTM net income YoY919.5%
TTM EPS YoY846.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin40.3%
Operating margin5.1%
Net margin2.8%
FCF margin9.6%
EBITDA margin11.2%
Returns
ROE2.8%
ROA1.5%
ROIC (approx.)3.6%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets44.4%
Debt / equity0.53x
Current ratio2.37x
Interest coverage1.41x
Cash quality & payout
Operating cash flow / net income4.63x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $560.44M | $551.68M | $530.23M | $540.70M | $536.99M | $548.87M | $604.70M | $629.80M |
| Cost of revenue | $325.69M | $316.63M | $324.00M | $337.72M | $336.11M | $340.80M | $394.59M | $402.55M |
| Gross profit | $234.75M | $235.05M | $206.23M | $202.99M | $200.88M | $208.06M | $210.11M | $227.26M |
| R&D expense | $21.75M | $22.70M | $21.28M | $21.09M | $21.25M | $21.87M | $23.29M | $22.36M |
| SG&A expense | $154.41M | $151.92M | $154.57M | $155.81M | $152.77M | $159.39M | $157.23M | $158.85M |
| Operating income | $52.32M | $39.13M | $13.58M | $5.63M | $13.72M | $10.59M | $12.89M | $37.69M |
| Interest expense | $15.24M | $15.75M | $16.49M | $30.95M | $19.81M | $20.55M | $22.03M | $34.24M |
| Pretax income | $36.18M | $23.14M | -$3.98M | -$15.90M | -$2.51M | $33.68M | -$10.91M | -$41.80M |
| Income tax | $7.19M | $7.07M | -$34.71M | -$2.65M | -$658,000 | $1.18M | $4.57M | $32.05M |
| Net income | $26.85M | $19.09M | $30.13M | -$15.73M | -$3.40M | $35.34M | -$15.48M | -$23.83M |
| EBITDA | $68.92M | $55.73M | $63.61M | $56.46M | $31.42M | $27.49M | $62.33M | $90.68M |
| EPS (basic) | 1.07 | 0.76 | 1.22 | — | -0.14 | 1.43 | -0.63 | — |
| EPS (diluted) | 1.07 | 0.76 | 1.20 | — | -0.14 | 1.43 | -0.63 | — |
| Weighted avg. shares (diluted) | 25.14M | 25.04M | 25.18M | — | 24.69M | 24.71M | 24.54M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $301.78M | $298.30M | $288.33M | $307.96M | $299.73M | $300.02M | $289.70M | $308.57M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $206.26M | $183.53M | $201.08M | $180.51M | $191.54M | $179.50M | $170.93M | $182.83M |
| Inventory | $607.27M | $607.42M | $605.59M | $615.86M | $622.44M | $616.47M | $590.33M | $584.68M |
| Current assets | $1.22B | $1.21B | $1.21B | $1.19B | $1.21B | $1.18B | $1.42B | $1.44B |
| PP&E, net | $444.99M | $446.80M | $445.13M | $451.82M | $455.97M | $452.44M | $441.98M | $442.75M |
| Goodwill | $1.48B | $1.48B | $1.49B | $1.50B | $1.50B | $1.50B | $1.46B | $1.43B |
| Intangibles | $536.47M | $567.66M | $598.97M | $633.56M | $664.83M | $698.01M | $716.67M | $740.79M |
| Total assets | $3.94B | $3.97B | $4.01B | $4.05B | $4.10B | $4.11B | $4.18B | $4.20B |
| Current liabilities | $514.63M | $498.36M | $517.90M | $498.86M | $492.90M | $482.78M | $549.02M | $556.18M |
| Short-term debt | $18.75M | $18.75M | $18.75M | $18.75M | $0 | $0 | $47.81M | $51.00M |
| Long-term debt | $1.13B | $1.21B | $1.26B | $1.27B | $1.31B | $1.34B | $1.49B | $1.53B |
| Total debt | $1.15B | $1.23B | $1.28B | $1.28B | $1.31B | $1.34B | $1.54B | $1.58B |
| Total liabilities | $1.75B | $1.82B | $1.90B | $1.93B | $1.98B | $1.99B | $2.20B | $2.24B |
| Shareholders' equity | $2.19B | $2.15B | $2.11B | $2.12B | $2.13B | $2.12B | $1.99B | $1.97B |
| Net debt | $850.07M | $932.90M | $992.25M | $976.70M | $1.01B | $1.04B | $1.25B | $1.27B |
| Shares outstanding | 25.01M | 25.01M | 24.99M | 24.69M | 24.69M | 24.68M | 24.61M | 24.52M |
| Cash flow statement | ||||||||
| Operating cash flow | $99.59M | $80.15M | $38.91M | $60.60M | $56.71M | $11.21M | $51.33M | $40.19M |
| Capital expenditure | $16.19M | $18.51M | $11.30M | $24.65M | $29.08M | $19.70M | $14.62M | $24.08M |
| Free cash flow | $83.40M | $61.64M | $27.61M | $35.95M | $27.63M | -$8.48M | $36.71M | $16.11M |
| Investing cash flow | -$13.93M | -$20.14M | -$11.21M | -$18.39M | -$30.03M | $187.46M | -$16.81M | -$26.55M |
| Financing cash flow | -$80.97M | -$50.23M | -$44.12M | -$34.48M | -$25.69M | -$195.01M | -$56.34M | -$8.19M |
| Depreciation & amortization | $16.60M | $16.60M | $50.03M | $50.83M | $17.70M | $16.90M | $49.45M | $52.99M |
| Stock-based compensation | $11.86M | $11.87M | $14.01M | $13.88M | $15.24M | $14.46M | $12.18M | $12.52M |
Free plan shows the latest 8 periods; Pro shows all 75 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.